Abstract
The search for an ideal anticoagulant has spanned decades and has resulted in several approaches and the identification of novel target molecules for preventing and treating thrombosis. The first group of new anticoagulant agents acting through direct inhibition of coagulation factors were inhibitors of thrombin, but factor Xa inhibitors and, most recently, factor VIIa inhibitors have become attractive candidates. The structures of thrombin, factor Xa and factor VIIa show similarities in their active sites and, for this reason, attempts have been made to develop synthetic agents containing in a single molecule inhibitory activity against two of the enzymes of the blood coagulation cascade. Such dual inhibitors are now in preclinical studies and are, potentially, new anticoagulant drugs with improved properties. The emphasis of this review will be placed on dual inhibitors of thrombin / factor Xa and factor Xa / factor VIIa. Comparison of the active sites of these enzymes is included for better understanding of the structural demands to be met in designing effective dual inhibitors.
Keywords: anticoagulants, dual inhibitors, thrombin, factor vIIa, factor xa
Current Medicinal Chemistry
Title: Dual Inhibitors of the Blood Coagulation Enzymes
Volume: 11 Issue: 19
Author(s): A. Kranjc and D. Kikelj
Affiliation:
Keywords: anticoagulants, dual inhibitors, thrombin, factor vIIa, factor xa
Abstract: The search for an ideal anticoagulant has spanned decades and has resulted in several approaches and the identification of novel target molecules for preventing and treating thrombosis. The first group of new anticoagulant agents acting through direct inhibition of coagulation factors were inhibitors of thrombin, but factor Xa inhibitors and, most recently, factor VIIa inhibitors have become attractive candidates. The structures of thrombin, factor Xa and factor VIIa show similarities in their active sites and, for this reason, attempts have been made to develop synthetic agents containing in a single molecule inhibitory activity against two of the enzymes of the blood coagulation cascade. Such dual inhibitors are now in preclinical studies and are, potentially, new anticoagulant drugs with improved properties. The emphasis of this review will be placed on dual inhibitors of thrombin / factor Xa and factor Xa / factor VIIa. Comparison of the active sites of these enzymes is included for better understanding of the structural demands to be met in designing effective dual inhibitors.
Export Options
About this article
Cite this article as:
Kranjc A. and Kikelj D., Dual Inhibitors of the Blood Coagulation Enzymes, Current Medicinal Chemistry 2004; 11 (19) . https://dx.doi.org/10.2174/0929867043364432
DOI https://dx.doi.org/10.2174/0929867043364432 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Purine Nucleoside Analogues for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Randomized Clinical Stroke Trials in 2006
Current Vascular Pharmacology Vascular Reactions of Iodinated X-Ray Contrast Media: Mechanisms and Possible Therapeutic Interventions
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Safety and Efficiency of Low Dose Intra-arterial Tirofiban in Mechanical Thrombectomy During Acute Ischemic Stroke
Current Neurovascular Research Focus on the Different Projects of Telemedicine Centered on the Elderly In France
Current Aging Science Conference Report: 10th International Summer School of Neurology: Celebrating a Decade of Success: 5th July, 2015 – 9th July, 2015 | Eforie Nord, Romania
CNS & Neurological Disorders - Drug Targets Self Destructive and Self Harm Behavior in Adolescence — An Integration of Dynamic and Empirical Psychological Models
Adolescent Psychiatry Pharmacological Profile of SSRIs and SNRIs in the Treatment of Eating Disorders
Current Clinical Pharmacology Commentary ( Two Hits with One Shot – A Possibility of Simultaneous Targeting Motor Neuron Loss and Depression in ALS by Upregulating ADAR2 )
CNS & Neurological Disorders - Drug Targets JNK Signalling: A Possible Target to Prevent Neurodegeneration
Current Pharmaceutical Design Recent Trend in the Chemistry of Triazolopyrimidines and their Applications
Mini-Reviews in Organic Chemistry Cell Cycle Re-Entry in Alzheimers Disease: A Major Neuropathological Characteristic?
Current Alzheimer Research Psychoactive Plants Described in a Brazilian Literary Work and their Chemical Compounds
Central Nervous System Agents in Medicinal Chemistry Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery Teenage-Pregnancies - A Biomedical and a Sociocultural Approach to a Current Problem
Current Women`s Health Reviews Editorial [Hot Topic: Food and Addiction: Implications and Relevance to Eating Disorders and Obesity (Guest Editor: Nicole M. Avena)]
Current Drug Abuse Reviews Synthesis, Biological Activity of Thiazolidinones Bearing Indoline Moiety and Isatin Based Hybrids
Mini-Reviews in Organic Chemistry Neuroinflammation and the Immune-Kynurenine Pathway in Anxiety Disorders
Current Neuropharmacology Sex Hormones and Brain Dopamine Functions
Central Nervous System Agents in Medicinal Chemistry Synthesis of Asymmetric 1-Thiocarbamoyl Pyrazoles as Potent Anti- Colon Cancer, Antioxidant and Anti-Inflammatory Agent
Anti-Cancer Agents in Medicinal Chemistry